University of Colorado

Musc Foundation for Research Development

National Jewish Health

National Jewish Medical and Research Center

Gary Gilkeson

V Michael Holers

Erwin W Gelfand

Stephen Tomlinson

Joshua M Thurman

Baerbel Rohrer

Christian Taube

Vernon Michael Holers

Michael Holers

The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.

Targeting complement factor H for treatment of diseases

Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

Inhibition of factor B, the alternative complement pathway and methods related thereto

Anti-factor B antibodies

Growing community of inventors

Charleston, SC, United States of America

Gary Gilkeson